A randomized, double blind, active control, flexible dose, multicenter study to evaluate galantamine HBr [hydrogen bromide] in the treatment of Alzheimer's disease:Safety and effectiveness of an immediate-release table formulation.

Trial Profile

A randomized, double blind, active control, flexible dose, multicenter study to evaluate galantamine HBr [hydrogen bromide] in the treatment of Alzheimer's disease:Safety and effectiveness of an immediate-release table formulation.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Donepezil; Galantamine
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 10 Sep 2011 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has been met.
    • 10 Sep 2011 Results presented at the 15th Congress of the European Federation of Neurological Societies.
    • 10 Sep 2011 Actual patient number changed as reported at the 15th Congress of the European Federation of Neurological Societies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top